Navigation Links
Treatment Advocates Challenge Patent for New Hepatitis C Drug
Date:11/24/2013

NEW YORK, Nov. 25, 2013 /PRNewswire-USNewswire/ -- The Open Society Foundations today welcomed a challenge in India to Gilead Science's patent application for their new medicine, sofosbuvir, by the Initiative for Medicines, Access & Knowledge.

The challenge, filed last week at the Kolkata Patent Office, would prevent Gilead from holding the monopoly on sofosbuvir's production and pricing. This would allow Indian manufacturers to produce a cheaper generic version of the medicine, a first step toward making it available other low-and middle-income countries.

Treatment with sofosbuvir is shorter than current treatments, has higher cure rates, can be taken orally, and is better tolerated. But these benefits are not the basis for a patent. And in India, the law states that products that are variants of existing chemical compounds are not patentable.

"Sofosbuvir is not innovative enough at the molecular level to warrant a patent," said Els Torreele, Director of the Open Society Foundations' Access to Essential Medicines Initiative. "This is a battle over whether profits or the lives of patients will drive the hepatitis C response."

Sofosbuvir is expected to be approved in the U.S. and in Europe in the coming weeks and could cost around $80,000 for a course of treatment. With 90% of hepatitis C patients living in low-and middle-income countries, this price tag will put the treatment out of reach for most.

"Without generic competition from India, patent-holding companies will be too slow bringing down prices," said Tahir Amin, Director of the Initiative for Medicines, Access & Knowledge. "This medicine is a variant of known compounds, and Indian law will not allow a company to make billions on it."

Dubbed a "viral time bomb" by the World Health Organization, there are an estimated 170 million people living with chronic hepatitis C globally—12 million of whom live in India. The disease infects nearly 4 million people each year and results in 350,000 deaths annually.

The Open Society Foundations is supporting patient groups and treatment advocates to increase access to hepatitis C treatment in many middle income countries—including Georgia, Ukraine, Vietnam, Thailand, Brazil, and Russia—where the price of even current Hepatitis treatments place them beyond reach.

The Open Society Foundations work to build vibrant and tolerant democracies whose governments are accountable to their citizens. Working with local communities in more than 100 countries, the Open Society Foundations support justice and human rights, freedom of expression, and access to public health and education.

The Initiative for Medicines, Access, & Knowledge (I-MAK) is a team of lawyers and scientists increasing access to affordable medicines by making sure the patent system works. Armed with the best evidence, I-MAK gives the public a voice in a system that impacts their health and lives. It is a grantee of the Open Society Foundations.


'/>"/>
SOURCE Open Society Foundations
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Large Vein Occlusive Disease: Diagnosis and Treatment Options to be Presented at the 40th Annual VEITHsymposium in New York
2. Phase IIb Study of Vanoxerine Shows Strong Safety and Statistically Significant Efficacy Signals for Treatment of Atrial Fibrillation
3. FDA Designates MST-188 As An Orphan Drug For Treatment Of Acute Limb Ischemia
4. Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease
5. IceCure Medical Ltd. announces treatment of first breast cancer patient using its IceSense3 Cryoablation System at John Wayne Cancer Institute
6. Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia
7. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
8. B. Braun to Launch New Level of Water Treatment Technology at ASN
9. NPC, UMD Study: Factors That Cause Different Treatment Responses Are Not Well Understood or Studied
10. Upsher-Smith To Present Findings From Global Phase 3 Trial Investigating USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures At 2013 American Epilepsy Society Meeting
11. Sorrento Therapeutics Enters into Antibody and Vaccine Development Alliance for the Prevention and Treatment of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... Mass. and SAN CLEMENTE, Calif. , ... California -based mobile pulmonary function testing company, is now able ... PFT devices developed by ndd Medical Technologies , Inc. ... testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® ... , can get any needed testing done in the comfort ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
Breaking Medicine News(10 mins):